Absolute 0 8 0 8 B-clinical_variable
neutrophil 9 19 9 19 I-clinical_variable
count 20 25 20 25 I-clinical_variable
≥ 26 27 26 27 O
1,500 28 33 28 33 B-lower_bound
/ 33 34 33 34 I-lower_bound
mc 34 36 34 36 I-lower_bound

Active 0 6 37 43 O
congestive 7 17 44 54 B-chronic_disease
heart 18 23 55 60 I-chronic_disease
failure 24 31 61 68 I-chronic_disease
( 32 33 69 70 O
New 33 36 70 73 B-clinical_variable
York 37 41 74 78 I-clinical_variable
heart 42 47 79 84 I-clinical_variable
Association 48 59 85 96 I-clinical_variable
Class 60 65 97 102 B-lower_bound
III 66 69 103 106 I-lower_bound
or 70 72 107 109 O
IV 73 75 110 112 B-upper_bound
) 75 76 112 113 O
, 76 77 113 114 O
symptomatic 78 89 115 126 O
ischemia 90 98 127 135 B-chronic_disease
, 98 99 135 136 O
or 100 102 137 139 O
conduction 103 113 140 150 O
abnormalities 114 127 151 164 O
uncontrolled 128 140 165 177 O
by 141 143 178 180 O
conventional 144 156 181 193 O
intervention 157 169 194 206 O
or 170 172 207 209 O
myocardial 173 183 210 220 B-chronic_disease
infarction 184 194 221 231 I-chronic_disease
within 195 201 232 238 O
four 202 206 239 243 B-upper_bound
months 207 213 244 250 I-upper_bound
prior 214 219 251 256 I-upper_bound
to 220 222 257 259 O
enrollment 223 233 260 270 O

Adequate 0 8 271 279 O
cardiac 9 16 280 287 O
function 17 25 288 296 O
left 26 30 297 301 B-clinical_variable
ventricular 31 42 302 313 I-clinical_variable
ejection 43 51 314 322 I-clinical_variable
fraction 52 60 323 331 I-clinical_variable
( 61 62 332 333 I-clinical_variable
LVEF 62 66 333 337 I-clinical_variable
) 66 67 337 338 I-clinical_variable
> 68 69 339 340 O
50 70 72 341 343 B-lower_bound
% 72 73 343 344 I-lower_bound
as 74 76 345 347 O
assessed 77 85 348 356 O
by 86 88 357 359 O
echocardiogram 89 103 360 374 B-treatment
or 104 106 375 377 O
MUGA 107 111 378 382 B-treatment
( 112 113 383 384 I-treatment
Multi 113 118 384 389 I-treatment
Gated 119 124 390 395 I-treatment
Acquisition 125 136 396 407 I-treatment
Scan 137 141 408 412 I-treatment
) 141 142 412 413 I-treatment

Age 0 3 414 417 B-age
≥ 4 5 418 419 O
60 6 8 420 422 B-lower_bound
( 9 10 423 424 O
1 10 11 424 425 O
point 12 17 426 431 O

Alanine 0 7 432 439 B-clinical_variable
aminotransferase 8 24 440 456 I-clinical_variable
( 25 26 457 458 I-clinical_variable
ALT 26 29 458 461 I-clinical_variable
) 29 30 461 462 I-clinical_variable
( 31 32 463 464 O
serum 32 37 464 469 B-clinical_variable
glutamate 38 47 470 479 I-clinical_variable
pyruvate 48 56 480 488 I-clinical_variable
transaminase 57 69 489 501 I-clinical_variable
[ 70 71 502 503 I-clinical_variable
SGPT 71 75 503 507 I-clinical_variable
] 75 76 507 508 I-clinical_variable
) 76 77 508 509 O
≤ 78 79 510 511 O
2.5 80 83 512 515 B-upper_bound
X 84 85 516 517 I-upper_bound
institutional 86 99 518 531 I-upper_bound
upper 100 105 532 537 I-upper_bound
limit 106 111 538 543 I-upper_bound
of 112 114 544 546 I-upper_bound
normal 115 121 547 553 I-upper_bound

Ann 0 3 554 557 B-clinical_variable
Arbor 4 9 558 563 I-clinical_variable
stage 10 15 564 569 I-clinical_variable
III 16 19 570 573 B-lower_bound
or 20 22 574 576 O
IV 23 25 577 579 B-upper_bound
( 26 27 580 581 O
1 27 28 581 582 O
point 29 34 583 588 O
) 34 35 588 589 O

Aspartate 0 9 590 599 B-clinical_variable
aminotransferase 10 26 600 616 I-clinical_variable
( 27 28 617 618 I-clinical_variable
AST 28 31 618 621 I-clinical_variable
) 31 32 621 622 I-clinical_variable
( 33 34 623 624 O
serum 34 39 624 629 B-clinical_variable
glutamic 40 48 630 638 I-clinical_variable
oxaloacetic 49 60 639 650 I-clinical_variable
transaminase 61 73 651 663 I-clinical_variable
[ 74 75 664 665 I-clinical_variable
SGOT 75 79 665 669 I-clinical_variable
] 79 80 669 670 I-clinical_variable
) 80 81 670 671 I-clinical_variable
≤ 82 83 672 673 O
2.5 84 87 674 677 B-upper_bound
X 88 89 678 679 I-upper_bound
institutional 90 103 680 693 I-upper_bound
upper 104 109 694 699 I-upper_bound
limit 110 115 700 705 I-upper_bound
of 116 118 706 708 I-upper_bound
normal 119 125 709 715 I-upper_bound

Creatinine 0 10 716 726 B-clinical_variable
clearance 11 20 727 736 I-clinical_variable
≥ 21 22 737 738 O
45 23 25 739 741 B-lower_bound
mL 26 28 742 744 I-lower_bound
/ 28 29 744 745 I-lower_bound
min 29 32 745 748 I-lower_bound
calculated 33 43 749 759 O
by 44 46 760 762 O
Cockcroft 47 56 763 772 O
- 56 57 772 773 O
Gault 57 62 773 778 O

ECOG 0 4 779 783 B-clinical_variable
performance 5 16 784 795 I-clinical_variable
status 17 23 796 802 I-clinical_variable
≥ 24 25 803 804 O
2 26 27 805 806 B-lower_bound
( 28 29 807 808 O
1 29 30 808 809 O
point 31 36 810 815 O
) 36 37 815 816 O

Eastern 0 7 817 824 B-clinical_variable
Cooperative 8 19 825 836 I-clinical_variable
Oncology 20 28 837 845 I-clinical_variable
Group 29 34 846 851 I-clinical_variable
( 35 36 852 853 I-clinical_variable
ECOG 36 40 853 857 I-clinical_variable
) 40 41 857 858 I-clinical_variable
performance 42 53 859 870 I-clinical_variable
status 54 60 871 877 I-clinical_variable
≤ 61 62 878 879 O
2 63 64 880 881 B-upper_bound
; 64 65 881 882 O
performance 66 77 883 894 O
status 78 84 895 901 O
of 85 87 902 904 O
3 88 89 905 906 B-upper_bound
will 90 94 907 911 O
be 95 97 912 914 O
accepted 98 106 915 923 O
if 107 109 924 926 O
impairment 110 120 927 937 O
is 121 123 938 940 O
caused 124 130 941 947 O
by 131 133 948 950 O
DLBCL 134 139 951 956 O
complications 140 153 957 970 O
and 154 157 971 974 O
improvement 158 169 975 986 O
is 170 172 987 989 O
expected 173 181 990 998 O
once 182 186 999 1003 O
therapy 187 194 1004 1011 B-treatment
is 195 197 1012 1014 O
initiated 198 207 1015 1024 O

Hemoglobin 0 10 1025 1035 B-clinical_variable
≥ 11 12 1036 1037 O
7.0 13 16 1038 1041 B-lower_bound
g 17 18 1042 1043 I-lower_bound
/ 18 19 1043 1044 I-lower_bound
dl 19 21 1044 1046 I-lower_bound

History 0 7 1047 1054 O
of 8 10 1055 1057 O
allergic 11 19 1058 1066 O
reactions 20 29 1067 1076 O
attributed 30 40 1077 1087 O
to 41 43 1088 1090 O
compounds 44 53 1091 1100 O
of 54 56 1101 1103 O
similar 57 64 1104 1111 O
chemical 65 73 1112 1120 O
or 74 76 1121 1123 O
biologic 77 85 1124 1132 O
composition 86 97 1133 1144 O
to 98 100 1145 1147 O
carfilzomib 101 112 1148 1159 B-allergy_name
or 113 115 1160 1162 O
other 116 121 1163 1168 O
agents 122 128 1169 1175 O
( 129 130 1176 1177 O
R 130 131 1177 1178 B-allergy_name
- 131 132 1178 1179 I-allergy_name
CHOP 132 136 1179 1183 I-allergy_name
) 136 137 1183 1184 O
used 138 142 1185 1189 O
in 143 145 1190 1192 O
this 146 150 1193 1197 O
study 151 156 1198 1203 O

Human 0 5 1204 1209 B-chronic_disease
immunodeficiency 6 22 1210 1226 I-chronic_disease
virus 23 28 1227 1232 I-chronic_disease
( 29 30 1233 1234 I-chronic_disease
HIV)-positive 30 43 1234 1247 I-chronic_disease
patients 44 52 1248 1256 O
on 53 55 1257 1259 O
combination 56 67 1260 1271 B-treatment
antiretroviral 68 82 1272 1286 I-treatment
therapy 83 90 1287 1294 I-treatment
are 91 94 1295 1298 O
ineligible 95 105 1299 1309 O

Known 0 5 1310 1315 O
central 6 13 1316 1323 B-chronic_disease
nervous 14 21 1324 1331 I-chronic_disease
system 22 28 1332 1338 I-chronic_disease
( 29 30 1339 1340 I-chronic_disease
CNS 30 33 1340 1343 I-chronic_disease
) 33 34 1343 1344 I-chronic_disease
involvement 35 46 1345 1356 O
by 47 49 1357 1359 O
lymphoma 50 58 1360 1368 B-cancer

Lactate 0 7 1369 1376 B-clinical_variable
dehydrogenase 8 21 1377 1390 I-clinical_variable
( 22 23 1391 1392 I-clinical_variable
LDH 23 26 1392 1395 I-clinical_variable
) 26 27 1395 1396 I-clinical_variable
> 28 29 1397 1398 O
upper 30 35 1399 1404 B-lower_bound
limit 36 41 1405 1410 I-lower_bound
of 42 44 1411 1413 I-lower_bound
normal 45 51 1414 1420 I-lower_bound
( 52 53 1421 1422 I-lower_bound
1 53 54 1422 1423 I-lower_bound
point 55 60 1424 1429 I-lower_bound
) 60 61 1429 1430 I-lower_bound

Other 0 5 1431 1436 O
malignancies 6 18 1437 1449 B-cancer
within 19 25 1450 1456 O
the 26 29 1457 1460 O
past 30 34 1461 1465 B-upper_bound
3 35 36 1466 1467 I-upper_bound
years 37 42 1468 1473 I-upper_bound
except 43 49 1474 1480 O
for 50 53 1481 1484 O
adequately 54 64 1485 1495 O
treated 65 72 1496 1503 O
carcinoma 73 82 1504 1513 B-cancer
of 83 85 1514 1516 I-cancer
the 86 89 1517 1520 I-cancer
cervix 90 96 1521 1527 I-cancer
or 97 99 1528 1530 O
basal 100 105 1531 1536 B-cancer
or 106 108 1537 1539 O
squamous 109 117 1540 1548 B-cancer
cell 118 122 1549 1553 I-cancer
carcinomas 123 133 1554 1564 I-cancer
of 134 136 1565 1567 I-cancer
the 137 140 1568 1571 I-cancer
skin 141 145 1572 1576 I-cancer
, 145 146 1576 1577 O
or 147 149 1578 1580 O
low 150 153 1581 1584 O
- 153 154 1584 1585 O
risk 154 158 1585 1589 O
prostate 159 167 1590 1598 B-cancer
cancer 168 174 1599 1605 I-cancer
after 175 180 1606 1611 O
curative 181 189 1612 1620 B-treatment
therapy 190 197 1621 1628 I-treatment

Patients 0 8 1629 1637 O
may 9 12 1638 1641 O
have 13 17 1642 1646 O
received 18 26 1647 1655 O
brief 27 32 1656 1661 O
( 33 34 1662 1663 O
< 34 35 1663 1664 O
15 35 37 1664 1666 B-upper_bound
days 38 42 1667 1671 I-upper_bound
) 42 43 1671 1672 O
treatment 44 53 1673 1682 B-treatment
with 54 58 1683 1687 I-treatment
glucocorticoids 59 74 1688 1703 I-treatment
and/or 75 81 1704 1710 O
1 82 83 1711 1712 B-treatment
cycle 84 89 1713 1718 I-treatment
of 90 92 1719 1721 I-treatment
chemotherapy 93 105 1722 1734 I-treatment
such 106 110 1735 1739 O
as 111 113 1740 1742 O
R 114 115 1743 1744 B-treatment
- 115 116 1744 1745 I-treatment
CHOP 116 120 1745 1749 I-treatment
[ 121 122 1750 1751 O
or 122 124 1751 1753 O
some 125 129 1754 1758 O
component(s 130 141 1759 1770 O
) 141 142 1770 1771 O
thereof 143 150 1772 1779 O
] 150 151 1779 1780 O
for 152 155 1781 1784 O
the 156 159 1785 1788 O
diagnosis 160 169 1789 1798 O
of 170 172 1799 1801 O
B 173 174 1802 1803 B-cancer
- 174 175 1803 1804 I-cancer
cell 175 179 1804 1808 I-cancer
lymphoma 180 188 1809 1817 I-cancer
provided 189 197 1818 1826 O
they 198 202 1827 1831 O
had 203 206 1832 1835 O
all 207 210 1836 1839 O
necessary 211 220 1840 1849 O
staging 221 228 1850 1857 O
tests 229 234 1858 1863 O
performed 235 244 1864 1873 O
prior 245 250 1874 1879 O
to 251 253 1880 1882 O
R 254 255 1883 1884 O
- 255 256 1884 1885 O
CHOP 256 260 1885 1889 O
including 261 270 1890 1899 O
CT 271 273 1900 1902 B-treatment
and/or 274 280 1903 1909 O
PET 281 284 1910 1913 B-treatment
/ 284 285 1913 1914 I-treatment
CT 285 287 1914 1916 I-treatment
scans 288 293 1917 1922 I-treatment
, 293 294 1922 1923 O
echocardiogram 295 309 1924 1938 B-treatment
and 310 313 1939 1942 O
bone 314 318 1943 1947 B-treatment
marrow 319 325 1948 1954 I-treatment
biopsy 326 332 1955 1961 I-treatment
. 332 333 1961 1962 O
Treatment 334 343 1963 1972 B-treatment
must 344 348 1973 1977 O
occur 349 354 1978 1983 O
within 355 361 1984 1990 O
60 362 364 1991 1993 B-upper_bound
days 365 369 1994 1998 I-upper_bound
prior 370 375 1999 2004 I-upper_bound
to 376 378 2005 2007 O
enrollment 379 389 2008 2018 O

Patients 0 8 2019 2027 O
must 9 13 2028 2032 O
have 14 18 2033 2037 O
histologically 19 33 2038 2052 O
confirmed 34 43 2053 2062 O
diffuse 44 51 2063 2070 B-cancer
large 52 57 2071 2076 I-cancer
B 58 59 2077 2078 I-cancer
- 59 60 2078 2079 I-cancer
cell 60 64 2079 2083 I-cancer
lymphoma 65 73 2084 2092 I-cancer
( 74 75 2093 2094 I-cancer
DLBCL 75 80 2094 2099 I-cancer
) 80 81 2099 2100 I-cancer
; 81 82 2100 2101 O
patients 83 91 2102 2110 O
with 92 96 2111 2115 O
previously 97 107 2116 2126 O
diagnosed 108 117 2127 2136 O
indolent 118 126 2137 2145 B-cancer
lymphoma 127 135 2146 2154 I-cancer
( 136 137 2155 2156 O
follicular 137 147 2156 2166 B-cancer
lymphoma 148 156 2167 2175 I-cancer
and 157 160 2176 2179 O
marginal 161 169 2180 2188 B-cancer
zone 170 174 2189 2193 I-cancer
lymphoma 175 183 2194 2202 I-cancer
but 184 187 2203 2206 O
not 188 191 2207 2210 O
small 192 197 2211 2216 B-cancer
lymphocytic 198 209 2217 2228 I-cancer
lymphoma 210 218 2229 2237 I-cancer
) 218 219 2237 2238 O
who 220 223 2239 2242 O
have 224 228 2243 2247 O
transformed 229 240 2248 2259 O
to 241 243 2260 2262 O
DLBCL 244 249 2263 2268 O
are 250 253 2269 2272 O
eligible 254 262 2273 2281 O
only 263 267 2282 2286 O
if 268 270 2287 2289 O
they 271 275 2290 2294 O
have 276 280 2295 2299 O
not 281 284 2300 2303 O
previously 285 295 2304 2314 O
been 296 300 2315 2319 O
treated 301 308 2320 2327 O
for 309 312 2328 2331 O
indolent 313 321 2332 2340 O
lymphoma 322 330 2341 2349 O
. 330 331 2349 2350 O
For 332 335 2351 2354 O
the 336 339 2355 2358 O
Phase 340 345 2359 2364 O
II 346 348 2365 2367 O
study 349 354 2368 2373 O
, 354 355 2373 2374 O
patients 356 364 2375 2383 O
must 365 369 2384 2388 O
have 370 374 2389 2393 O
non 375 378 2394 2397 O
- 378 379 2397 2398 O
GC 379 381 2398 2400 O
DLBCL 382 387 2401 2406 O
as 388 390 2407 2409 O
determined 391 401 2410 2420 O
by 402 404 2421 2423 O
Hans 405 409 2424 2428 O
Algorithm 410 419 2429 2438 O

Patients 0 8 2439 2447 O
who 9 12 2448 2451 O
are 13 16 2452 2455 O
receiving 17 26 2456 2465 O
any 27 30 2466 2469 O
other 31 36 2470 2475 O
investigational 37 52 2476 2491 B-treatment
agents 53 59 2492 2498 I-treatment

Patients 0 8 2499 2507 O
who 9 12 2508 2511 O
are 13 16 2512 2515 O
reported 17 25 2516 2524 O
to 26 28 2525 2527 O
be 29 31 2528 2530 O
of 32 34 2531 2533 O
direct 35 41 2534 2540 O
Asian 42 47 2541 2546 B-ethnicity
- 47 48 2546 2547 I-ethnicity
Pacific 48 55 2547 2554 I-ethnicity
( 56 57 2555 2556 I-ethnicity
China 57 62 2556 2561 I-ethnicity
, 62 63 2561 2562 I-ethnicity
Japan 64 69 2563 2568 I-ethnicity
, 69 70 2568 2569 I-ethnicity
Taiwan 71 77 2570 2576 I-ethnicity
, 77 78 2576 2577 I-ethnicity
Singapore 79 88 2578 2587 I-ethnicity
, 88 89 2587 2588 I-ethnicity
Republic 90 98 2589 2597 I-ethnicity
of 99 101 2598 2600 I-ethnicity
Korea 102 107 2601 2606 I-ethnicity
, 107 108 2606 2607 I-ethnicity
and 109 112 2608 2611 I-ethnicity
Thailand 113 121 2612 2620 I-ethnicity
) 121 122 2620 2621 I-ethnicity
ancestry 123 131 2622 2630 I-ethnicity

Patients 0 8 2631 2639 O
who 9 12 2640 2643 O
have 13 17 2644 2648 O
had 18 21 2649 2652 O
major 22 27 2653 2658 O
surgical 28 36 2659 2667 O
procedures 37 47 2668 2678 O
or 48 50 2679 2681 O
significant 51 62 2682 2693 O
traumatic 63 72 2694 2703 B-chronic_disease
injury 73 79 2704 2710 I-chronic_disease
within 80 86 2711 2717 O
28 87 89 2718 2720 B-upper_bound
days 90 94 2721 2725 I-upper_bound
prior 95 100 2726 2731 I-upper_bound
to 101 103 2732 2734 O
study 104 109 2735 2740 O
treatment 110 119 2741 2750 B-treatment

Patients 0 8 2751 2759 O
who 9 12 2760 2763 O
have 13 17 2764 2768 O
not 18 21 2769 2772 O
recovered 22 31 2773 2782 O
from 32 36 2783 2787 O
adverse 37 44 2788 2795 O
events 45 51 2796 2802 O
due 52 55 2803 2806 O
to 56 58 2807 2809 O
agents 59 65 2810 2816 O
administered 66 78 2817 2829 O
more 79 83 2830 2834 O
than 84 88 2835 2839 O
4 89 90 2840 2841 B-lower_bound
weeks 91 96 2842 2847 I-lower_bound
earlier 97 104 2848 2855 I-lower_bound

Patients 0 8 2856 2864 O
with 9 13 2865 2869 O
uncontrolled 14 26 2870 2882 O
intercurrent 27 39 2883 2895 O
illness 40 47 2896 2903 O
including 48 57 2904 2913 O
, 57 58 2913 2914 O
but 59 62 2915 2918 O
not 63 66 2919 2922 O
limited 67 74 2923 2930 O
to 75 77 2931 2933 O
ongoing 78 85 2934 2941 O
or 86 88 2942 2944 O
active 89 95 2945 2951 B-chronic_disease
infection 96 105 2952 2961 I-chronic_disease
, 105 106 2961 2962 O
or 107 109 2963 2965 O
psychiatric 110 121 2966 2977 B-chronic_disease
illness 122 129 2978 2985 I-chronic_disease
/ 129 130 2985 2986 O
social 130 136 2986 2992 O
situations 137 147 2993 3003 O
that 148 152 3004 3008 O
would 153 158 3009 3014 O
limit 159 164 3015 3020 O
compliance 165 175 3021 3031 O
with 176 180 3032 3036 O
study 181 186 3037 3042 O
requirements 187 199 3043 3055 O

Platelet 0 8 3056 3064 B-clinical_variable
count 9 14 3065 3070 I-clinical_variable
≥ 15 16 3071 3072 O
100,000 17 24 3073 3080 B-lower_bound
/ 24 25 3080 3081 I-lower_bound
mcL 25 28 3081 3084 I-lower_bound

Pregnant 0 8 3085 3093 B-pregnancy

The 0 3 3094 3097 O
effects 4 11 3098 3105 O
of 12 14 3106 3108 O
Carfilzomib 15 26 3109 3120 B-treatment
on 27 29 3121 3123 O
the 30 33 3124 3127 O
developing 34 44 3128 3138 O
human 45 50 3139 3144 O
fetus 51 56 3145 3150 O
are 57 60 3151 3154 O
unknown 61 68 3155 3162 O
. 68 69 3162 3163 O
For 70 73 3164 3167 O
this 74 78 3168 3172 O
reason 79 85 3173 3179 O
and 86 89 3180 3183 O
because 90 97 3184 3191 O
chemotherapeutic 98 114 3192 3208 B-treatment
agents 115 121 3209 3215 I-treatment
used 122 126 3216 3220 O
in 127 129 3221 3223 O
this 130 134 3224 3228 O
study 135 140 3229 3234 O
are 141 144 3235 3238 O
known 145 150 3239 3244 O
to 151 153 3245 3247 O
be 154 156 3248 3250 O
teratogenic 157 168 3251 3262 O
, 168 169 3262 3263 O
women 170 175 3264 3269 B-gender
of 176 178 3270 3272 O
child 179 184 3273 3278 O
- 184 185 3278 3279 O
bearing 185 192 3279 3286 O
potential 193 202 3287 3296 O
and 203 206 3297 3300 O
men 207 210 3301 3304 O
must 211 215 3305 3309 O
agree 216 221 3310 3315 B-contraception_consent
to 222 224 3316 3318 I-contraception_consent
use 225 228 3319 3322 I-contraception_consent
adequate 229 237 3323 3331 I-contraception_consent
contraception 238 251 3332 3345 I-contraception_consent
( 252 253 3346 3347 O
double 253 259 3347 3353 B-contraception_consent
barrier 260 267 3354 3361 I-contraception_consent
method 268 274 3362 3368 I-contraception_consent
of 275 277 3369 3371 I-contraception_consent
birth 278 283 3372 3377 I-contraception_consent
control 284 291 3378 3385 I-contraception_consent
or 292 294 3386 3388 O
abstinence 295 305 3389 3399 B-contraception_consent
) 305 306 3399 3400 O
2 307 308 3401 3402 B-upper_bound
weeks 309 314 3403 3408 I-upper_bound
prior 315 320 3409 3414 I-upper_bound
to 321 323 3415 3417 O
initiation 324 334 3418 3428 O
of 335 337 3429 3431 O
treatment 338 347 3432 3441 B-treatment
, 347 348 3441 3442 O
for 349 352 3443 3446 O
the 353 356 3447 3450 O
duration 357 365 3451 3459 O
of 366 368 3460 3462 O
study 369 374 3463 3468 O
participation 375 388 3469 3482 O
and 389 392 3483 3486 O
for 393 396 3487 3490 O
3 397 398 3491 3492 B-upper_bound
months 399 405 3493 3499 I-upper_bound
after 406 411 3500 3505 I-upper_bound
completing 412 422 3506 3516 O
treatment 423 432 3517 3526 O
. 432 433 3526 3527 O
Should 434 440 3528 3534 O
a 441 442 3535 3536 O
woman 443 448 3537 3542 B-gender
become 449 455 3543 3549 B-pregnancy
pregnant 456 464 3550 3558 I-pregnancy
or 465 467 3559 3561 O
suspect 468 475 3562 3569 O
that 476 480 3570 3574 O
she 481 484 3575 3578 O
is 485 487 3579 3581 O
pregnant 488 496 3582 3590 O
while 497 502 3591 3596 O
she 503 506 3597 3600 O
or 507 509 3601 3603 O
her 510 513 3604 3607 O
partner 514 521 3608 3615 O
is 522 524 3616 3618 O
participating 525 538 3619 3632 O
in 539 541 3633 3635 O
this 542 546 3636 3640 O
study 547 552 3641 3646 O
, 552 553 3646 3647 O
she 554 557 3648 3651 O
should 558 564 3652 3658 O
inform 565 571 3659 3665 O
the 572 575 3666 3669 O
treating 576 584 3670 3678 O
physician 585 594 3679 3688 O
immediately 595 606 3689 3700 O
. 606 607 3700 3701 O
Men 608 611 3702 3705 B-gender
must 612 616 3706 3710 O
agree 617 622 3711 3716 O
to 623 625 3717 3719 O
refrain 626 633 3720 3727 O
from 634 638 3728 3732 O
sperm 639 644 3733 3738 O
donation 645 653 3739 3747 O
for 654 657 3748 3751 O
at 658 660 3752 3754 O
least 661 666 3755 3760 O
90 667 669 3761 3763 B-lower_bound
days 670 674 3764 3768 I-lower_bound
after 675 680 3769 3774 I-lower_bound
the 681 684 3775 3778 O
last 685 689 3779 3783 O
dose 690 694 3784 3788 O
of 695 697 3789 3791 O
carfilzomib 698 709 3792 3803 B-treatment

Total 0 5 3804 3809 B-clinical_variable
bilirubin 6 15 3810 3819 I-clinical_variable
within 16 22 3820 3826 O
normal 23 29 3827 3833 O
institutional 30 43 3834 3847 O
limits 44 50 3848 3854 O
unless 51 57 3855 3861 O
due 58 61 3862 3865 O
to 62 64 3866 3868 O
Gilbert 65 72 3869 3876 B-chronic_disease
's 72 74 3876 3878 I-chronic_disease
disease 75 82 3879 3886 I-chronic_disease

breastfeeding 0 13 3887 3900 O
women 14 19 3901 3906 B-gender
are 20 23 3907 3910 O
excluded 24 32 3911 3919 O
from 33 37 3920 3924 O
this 38 42 3925 3929 O
study 43 48 3930 3935 O
; 48 49 3935 3936 O
breastfeeding 50 63 3937 3950 O
should 64 70 3951 3957 O
be 71 73 3958 3960 O
discontinued 74 86 3961 3973 O
if 87 89 3974 3976 O
the 90 93 3977 3980 O
mother 94 100 3981 3987 O
is 101 103 3988 3990 O
treated 104 111 3991 3998 O
with 112 116 3999 4003 O
carfilzomib 117 128 4004 4015 B-treatment

≥ 0 1 4016 4017 O
2 2 3 4018 4019 B-lower_bound
extranodal 4 14 4020 4030 B-cancer
sites 15 20 4031 4036 I-cancer
( 21 22 4037 4038 O
1 22 23 4038 4039 O
point 24 29 4040 4045 O
) 29 30 4045 4046 O

